Mazdutide is a dual agonist of the GLP-1receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM).
The drug is developed by Eli Lilly and is currently in multiple Phase III studies.
In May 2025, a result of Phase III study has shown that once-weekly mazdutide led to clinically relevant reductions in body weight in Chinese adults with overweight or obesity.
